Tender Details

Country: USA
Summary: Screen the A10 antibody for offtarget binding to plasma membrane proteins and secreted proteins
UST Ref No: 133408517
Deadline: 15 Jan 2026
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.:
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE ORDER AND NOT A REQUEST FOR QUOTATIONS.
This contract action is for the acquisition of services for which the Government intends to solicit and negotiate with only one source under the authority of Federal Acquisition Regulation (FAR) Subpart 13.106-1(b). The National Cancer Institute (NCI) intends to award a single source purchase order to Charles River Discovery Research Services UK Limited, Unit 3/4 High Peak Business Park, Buxton Road, Chinley, High Peak, SK23 6FJ, UK, for the acquisition of the screen of the A10 antibody for off-target binding to plasma membrane proteins and secreted proteins.
The National Cancer Institute (NCI) has a program to use an antibody called, 'A10' to target cancer cells that have a lot of the epidermal growth factor receptor on their cell surface. While this antibody has been extensively tested and characterized it is not known if it also binds any other cell surface proteins. The contractor shall perform an off-target screen on an NCI antibody and report back on any problematic interactions that could predict a serious side effect should the antibody be given to a cancer patient. The A10 is NOT known to bind other cell surface proteins or secreted proteins but this needs to be addressed in the off-target screen.
The anticipated period of performance will be 10-12 weeks after award.
The applicable North American Industry Classification System (NAICS) code for this acquisition is 541380 - Testing Laboratories and Services and a size standard of $19M.
NCI will solicit and negotiate directly with Charles River Discovery Research Services UK Limited and no solicitation will be issued. Interested parties may identify their interest and capability. Award is subject to approval of the Sole Source Justification. This notice of intent is not a request for competitive proposals or quotations; however, an interested party may submit a statement of capabilities if they believe they...
Documents:

If you are registered member, kindly login to view full details of this tender notice:

Screen the A10 antibody for offtarget binding to plasma membrane proteins and secreted proteins - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ITY-RESULT _NGCONTENT-NG-C2559963487="" _NGHOST-NG-C893956049="" CLASS="NG-STAR-INSERTED" SCREEN THE A10 ANTIBODY FOR OFF-TARGET BINDING TO PLASMA MEMBRANE PROTEINS AND SECRETED PROTEINS., a Government sector organization in USA, has announced a new tender for Screen the A10 antibody for offtarget binding to plasma membrane proteins and secreted proteins. This tender is published on USARFP under UST Ref No: 133408517 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-15.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.